HomeCompareGTH vs NOBL

GTH vs NOBL: Dividend Comparison 2026

GTH yields 49.69% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GTH wins by $364.9K in total portfolio value
10 years
GTH
GTH
● Live price
49.69%
Share price
$4.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$387.7K
Annual income
$78,189.68
Full GTH calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — GTH vs NOBL

📍 GTH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGTHNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GTH + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GTH pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GTH
Annual income on $10K today (after 15% tax)
$4,223.60/yr
After 10yr DRIP, annual income (after tax)
$66,461.23/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, GTH beats the other by $66,248.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GTH + NOBL for your $10,000?

GTH: 50%NOBL: 50%
100% NOBL50/50100% GTH
Portfolio after 10yr
$205.3K
Annual income
$39,219.73/yr
Blended yield
19.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GTH right now

GTH
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-8.9
Piotroski
4/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GTH buys
0
NOBL buys
0
No recent congressional trades found for GTH or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGTHNOBL
Forward yield49.69%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$387.7K$22.9K
Annual income after 10y$78,189.68$249.78
Total dividends collected$308.9K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GTH vs NOBL ($10,000, DRIP)

YearGTH PortfolioGTH Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$15,669$4,968.94$10,917$217.08+$4.8KGTH
2$24,042$7,276.46$11,903$221.48+$12.1KGTH
3$36,160$10,434.49$12,962$225.68+$23.2KGTH
4$53,358$14,666.87$14,099$229.68+$39.3KGTH
5$77,320$20,226.76$15,319$233.49+$62.0KGTH
6$110,125$27,392.67$16,628$237.10+$93.5KGTH
7$154,296$36,462.43$18,033$240.53+$136.3KGTH
8$212,842$47,745.39$19,539$243.78+$193.3KGTH
9$289,294$61,553.22$21,154$246.86+$268.1KGTH
10$387,734$78,189.68$22,884$249.78+$364.9KGTH

GTH vs NOBL: Complete Analysis 2026

GTHStock

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Full GTH Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this GTH vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GTH vs SCHDGTH vs JEPIGTH vs OGTH vs KOGTH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.